Marathon Petroleum STRIVES for Investment-Return Balance and 4 Stocks Jumping to 52-Week Highs
Medidata Solutions (NASDAQ:MDSO) reports a Q2 adjusted EPS 23c, consensus 23c. The shares closed at $35.41, up $4.24 or 13.6% on the day. They have traded in a 52-week range of $14.07 to $33.25.
Don’t Miss: Apple Reaches Court In ATTACK Mode.
Marathon Petroleum (MPC) CEO Gary R. Heminger stated: “This represented an important component of MPC’s ongoing plan to return capital to shareholders with $1.15B remaining under the current $2 billion share repurchase authorization. We remain committed to maximizing total returns to our shareholders, and recognize the trust our investors have placed in us to exercise discipline in the allocation of capital. We will continue to strike a balance between making value-enhancing investments in our business and returning capital to shareholders. Our recent decision to increase the quarterly dividend from 25c to 35c per share further underscores this commitment.” The shares closed at $47.30, down $0.17 or 0.36% on the day. They have traded in a 52-week range of $26.35 to $47.94.
Nisource Inc (NYSE:NI): The construction is to occur in Western Pennsylvania. The shares closed at $25.59, down $0.04 or 0.16% on the day. They have traded in a 52-week range of $17.95 to $25.84.
Pfizer (NYSE:PFE) announced its top-line results from ORAL Start, a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase inhibitor for to treat adults with moderate-to-severe active rheumatoid arthritis. ORAL Start, a continuing two-year study in methotrexate (NYSE:MTX)-nave patients with moderate-to-severe active RA, randomized to receive tofacitinib 5 or 10 mg twice-daily as monotherapy or MTX, met its primary endpoints at both the 5 and 10 mg BID doses. Tofacitinib was revealed to be superior to MTX with statistically noticeable changes shown in the inhibition of structural damage, as measured by change from baseline in modified Total Sharp Score, and in the reduction of signs and symptoms of RA, as measured by ACR70 response rates. Both primary endpoints assessed tofacitinib compared to MTX at six months. The data reported is from a planned analysis at one year. The shares closed at $24.04, up $0.33 or 1.39% on the day. They have traded in a 52-week range of $16.63 to $23.94.
Phillips 66 Common (PSX): Notable companies who reported before the opening bell are AGL Resources (NYSE:GAS), Allergan (NYSE:AGN), Automatic Data Processing (NASDAQ:ADP), American Tower (NYSE:AMT), Avon Products (NYSE:AVP), Comcast (NASDAQ:CMCSA), Devon Energy (NYSE:DVN), Dominion Resources (NYSE:D), Exelon (NYSE:EXC), Harley-Davidson (NYSE:HOG), Hospira (NYSE:HSP), IntercontinentalExchange (NYSE:ICE), Marathon Oil (NYSE:MRO), MasterCard (NYSE:MA), Phillips 66 (PSX), R.R. Donnelley & Sons (NASDAQ:RRD), Time Warner (NYSE:TWX) and Wisconsin Energy (NYSE:WEC). The shares closed at $37.60, down $0.05 or 0.13% on the day. They have traded in a 52-week range of $28.75 to $37.67.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.